New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
08:37 EDTBMRNBioMarin sees FY14 revenue $650M-$680M, consensus $670.4M
BioMarin Pharmaceutical sees FY14 revenues $650M-$680M, including Naglazyme product revenue $290M-$310M, Kuvan product revenue $180M-$200M and VIMIZIM revenue $60M-$70M. Sees FY14 SG&A expense $265M-$285M, R&D expense $500M-$530M and non-GAAP net loss ($100M)-($130M). Guidance issued in slides for conference call.
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 12, 2014
07:53 EDTBMRNLeerink to hold a tour
Subscribe for More Information
November 10, 2014
10:04 EDTBMRNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:02 EDTBMRNBioMarin upgraded to Buy from Neutral at Goldman
Goldman upgraded BioMarin to Buy based on increased confidence in BMN-111 for achondroplasia with expected proof-of-concept data in Q2 2015. The firm now sees a greater than 50% probability of success and peak sales of $900M. Price target raised to $104 from $78.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use